A Phase 3 interventional study of Metformin and Placebo in Obesity and Cardiovascular Risk, Insulin Resistance and Obesity (Body Mass Index >30 kg/m2), sponsored by University Of Nigeria Teaching Hospital. Recruiting at 2 sites in Nigeria. Open to participants aged 20 Years to 59 Years. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by University Of Nigeria Teaching Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing metformin in Obesity — 15 open to participants now, 17 under way, 3 of them phase 3. Metformin · Obesity.
Among the 81 studies testing metformin in Obesity, this one is the 8th largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 10 of the 16 other live ones, and was the 73rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →15 of the 81 studies testing metformin in Obesity are open now, in 9 countries. Recruiting first, the newest first:
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Riphah International University · Sites in Pakistan
Healthy volunteers
Fazaia Ruth Pfau Medical College · Sites in Pakistan
Ages 18–45
Fudan University · Sites in China
Ages 60–75
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 20 Years to 59 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 13 · Phase 4 29
First in 1996; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 62 across the 81 interventional studies. Of the 55 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 81 have an industry lead sponsor. The 10 most frequent:
University Of Nigeria Teaching Hospital is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
University Of Nigeria Teaching Hospital has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
8 of the studies testing metformin in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07297290Phase 3University Of Nigeria Teaching HospitalEffect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI) | 2027-03-31 |
| NCT07622290Phase 3Prof Ibrahim JanahiMetformin Treatment for Children With Obesity-associated Asthma | 2027-08 |
| NCT07550816Beijing QL Biopharmaceutical Co.,LtdDrug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | 2026-12-05 |
| NCT06273072Johns Hopkins UniversityMetformin IN Asthma for Overweight and Obese Individuals (MINA) | 2026-12-31 |
| NCT05744479Centre for Addiction and Mental HealthMetformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability | 2027-03-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 81 studies testing metformin in Obesity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.
Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Obesity (defined as ≥ 30kg/m2),
Exclusion Criteria:
Obesity (defined as ≥ 30kg/m2),
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin 500mg extended release tablets taken once daily to a maximum dose of 1500mg daily
Drug: Metformin
Identical-looking placebo
Drug: Placebo
Metformin 500mg extended release tablets taken to a maximum of 1500mg once daily
Starch-based, identical looking placebo
Effect of Metformin on body weight change
Determine percent change in body weight in kilograms and height in meters which will be combined to report BMI in kg/m2 among the treatment arm and compared to the control arm.
Time frame: 24 months
Effect of Metformin on Cardiovascular risk
Determine percent change in the 10 year Framingham risk score for cardiovascular disease among the treatment arm and compare with the control arm.
Time frame: 24 months
Effect of Metformin on insulin resistance in non-diabetics
Determine percent change in the insulin resistance indices using Homeostatic model assessment (HOMA) among the treatment arm and compare to the control arm.
Time frame: 24 months
Effect of metformin on waist circumference change
Determine the percent change in waist circumference measured in cm at baseline and final readings among the treatment arm and compared to the control arm.
Time frame: 24 months
Effect of metformin on waist-to-hip circumference change
Determine the percent change in waist circumference measured in cm, and hip circumference measured in cm, which will be combined to report waist-to-hip circumference ratio change among the treatment arm and compared to the control arm.
Time frame: 24 months
Safety of Metformin extended release tablet taken daily
Determine the incidence of adverse effects at grade 3 or higher level using the Adverse Effect questionnaire when dosage of less than or equal to 1500mg of Metformin X extended release tablet is taken daily.
Time frame: 24 months
Percent drug compliance to Metformin extended release taken once daily.
Determine the percent drug compliance to administered Metformin extended release tablets, determined by count of actual number of drug tablets administered over count of what was expected to have been administered, expressed as a percentage.
Time frame: 24 months
Plan to share: Yes — Study protocol, statistical analysis plan, informed consent form, Non-identifiable patient measurements.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available after publishing of the research work likely from 1 Jan 2029 for 5 years (31 Dec 2033)
Access criteria: The research institution, the research funders, potential collaborators and funders.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.
Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's planned 20 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
University Of Nigeria Teaching Hospital